<?xml version="1.0" encoding="UTF-8"?>
<p id="para220">The primary endpoint of the trial was the proportion of patients who achieved an investigator-assessed, CT-based complete response or unconfirmed complete response on completion of study chemotherapy, according to the International Workshop Standardized Response Criteria for non-Hodgkin lymphoma.
 <xref rid="bib22" ref-type="bibr">
  <sup>22</sup>
 </xref>
</p>
